Gamida Cell

company

About

Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases.

  • 101 - 250

Details

Last Funding Type
Series D
Last Funding Money Raised
$16M
Industries
Biotechnology,Health Care,Life Science,Medical Device,Therapeutics
Founded date
Jan 1, 1998
Number Of Employee
101 - 250
Operating Status
Active

Gamida Cell is a biopharmaceutical company developing advanced cell therapies for patients with blood cancers and hematologic diseases. Its product includes NiCord, a cell therapy based on NAM-expanded cord blood developed to improve and extend the life-saving benefits of hematopoietic stem cell transplant. The company applies an expansion platform supporting the properties of NAM to allogeneic cell sources that include omidubicel, an investigational product with potential as a life-saving alternative for patients in need of bone marrow transplant.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
$26M
Gamida Cell has raised a total of $26M in funding over 2 rounds. Their latest funding was raised on May 15, 2012 from a Series E round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 15, 2012 Series E $10M 1 Detail
Sep 27, 2006 Series D $16M 2 Detail

Investors

Number of Lead Investors
Number of Investors
2
Gamida Cell is funded by 2 investors. Denali Ventures and Elscint Biomedical Investment are the most recent investors.
Investor Name Lead Investor Funding Round
Denali Ventures Series E
Elscint Biomedical Investment Series D